Mount Sinai
BioMark Diagnostics, Icahn Mount Sinai to Develop Multiomic Lung Cancer Tests
The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics.
The analysis of three clinical trials also suggested that NTRK fusion-positive colorectal cancers don't respond as well as other tumors to Rozlytrek.
Ahead of an expected radiopharmaceutical approval in the New Year, oncologists and drugmakers are taking stock of imaging eligibility requirements and access disparities.
Gene Expression Signature IDs Multiple Myeloma Best Responders to Karyopharm's Xpovio in ASH Study
Researchers are now conducting additional research to understand why these genes in the signature are associated with response.
Multiple Myeloma Patient Similarity Network Reveals Prognostically Informative Subgroups
Researchers identified 12 multiple myeloma subgroups based on mutation, copy number, chromosomal rearrangement, and expression features in more than 650 tumors.